The study aimed to investigate the frequency and severity of skin rash-like symptoms known as exanthema and its relationship with treatment outcome with vemurafenib (Zelboraf) alone or vemurafenib combined with cobimetinib (Cotellic) in patients with advanced melanoma. The study showed that the appearance of exanthema within 6 weeks of starting treatment was associated with good outcomes in these patients.

This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the 12-month visit with a TT switch within 6 months.

This study explored the effects of different second-line therapies combined with metformin (Glucophage) in patients with type 2 diabetes (T2D). The data showed that metformin combinations with a sulfonylurea (SU) had the lowest weight loss, the smallest effect of lowering blood glucose, and an overall, reduced health status.

This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients.

This study compared the safety and effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) versus lapatinib (Tykerb) plus capecitabine in patients with human epidermal growth factor (HER2)-positive breast cancer (BC) spread (metastases) to the central nervous system (CNS; brain and spinal cord). The data showed that the neratinib plus capecitabine combination significantly improved survival without cancer worsening and CNS outcomes for these patients.

This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better treatment outcomes in these patients.

This study aimed to investigate depression and cognitive (thinking and reasoning) functions after taxane-based chemotherapy in patients with breast cancer. 

This study concluded taxane-based chemotherapy commonly leads to cognitive impairment in these patients, but some functions improve or remain stable after stopping treatment.

This study compared the benefit of two doses of filgotinib (Jyseleca) with adalimumab (Humira) and placebo, in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX; Otrexup). The data showed that filgotinib reduced RA signs, improved physical activity, prevented structural joint damage progression, and was well-tolerated in patients with inadequate responses to MTX.

This analysis was carried out to assess the outcomes of patients who underwent surgery only or surgery and chemotherapy (CT) for limited-stage small-cell lung cancer (LS-SCLC). The authors found that surgery plus CT resulted in better outcomes compared to surgery alone. 

This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients.